Unanswered questions regarding the management of sunitinib-induced hypothyroidism

Nature Clinical Practice Oncology

Volumn 4, Issue 12, 2007, Pages 674-675

  Garfield, David ^a   Hercbergs, Aleck ^b   Davis, Paul ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEXAROTENE; IMATINIB; INTEGRIN RECEPTOR; INTERLEUKIN 12; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TETRAIODOTHYROACETIC ACID; THYROID HORMONE; THYROTROPIN; THYROXINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN;

BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; DRUG EFFICACY; DRUG MECHANISM; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; KIDNEY CARCINOMA; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; THYROIDECTOMY; TUMOR CELL; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; HYPOTHYROIDISM; INDOLES; NEOPLASMS; PYRROLES; THYROID HORMONES;

EID: 36549031784     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0998     Document Type: Review

References (13)

1. Rini BI et al. (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99: 81-83
2. Desai J et al. (2006) Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145: 660-664
3. Wong E et al. (2007) Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17: 351-355
4. Kamba T et al. (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290: H560-H576
5. de Groot JWB et al. (2005) Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 78: 433-438
6. Davis PJ et al. (2006) Cell surface receptor for thyroid hormone and tumor cell proliferation. Expert Rev Endocrin Metab 1: 753-761
7. Nelson M et al. (2006) Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 132: 1041-1046
8. Hercbergs A (1999) Spontaneous remission of cancer-a thyroid hormone dependent phenomenon? Anticancer Res 19: 4839-4844
9. Golden WM et al. (2007) Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. J Clin Endocrinol Metab 92: 124-130
10. Govindan R et al. (2006) Phase II trial of bexarotene capsules in patients with advanced non-small cell lung cancer after failure of two or more previous therapies. J Clin Oncol 24: 4848-4854
11. Lin HY et al. (2007) Thyroid hormone is a MAPK-dependent growth factor thyroid cancer cells and is anti-apoptotic. Steroids 72 180-187
12. Dedecjus M et al. (2007) Influence of L-thyroxine administration on poor-platelet plasma VEGF concentrations in patients with induced short-term hypothyroidism, monitored for thyroid carcinoma. Endocr J 54: 63-69
13. Surks ML et al. (2004) Subclinical thyroid disease: Scientific review and guidelines for diagnosis and management. JAMA 291 228-238